Leqembi, the first medication to treat the memory disorder, is now available in a self-injecting pen, TIME Magazine reported.

Described as “the first at-home treatment for Alzheimer’s”, the drug was approved by the U.S. Food and Drug Administration (FDA) in 2023.

From TIME’s coverage:

The self-injectable version works in a similar way to the auto-injector pens that deliver weight-loss drugs like Wegovy and Zepbound, and could make the Alzheimer’s drug accessible to more people. In January 2025, the FDA approved lecanemab for maintenance therapy, but patients still had to get the drug via infusion at infusion centers. Now, Iqlik will give people more flexibility to continue their treatment. Once they complete the initial treatment regimen over 18 months with the IV version of lecanemab, they can either continue to get an IV infusion of the maintenance dose or give themselves an injection—or switch back and forth, says Kramer. 

For patients without insurance, the cost for a year’s supply of Iqlik will be $19,500 according to Eisai, compared to $13,316 for a year of the IV maintenance therapy. Medicare currently covers lecanemab if doctors enroll patients in a registry, and costs for those with Medicare Part D are capped at $2,000 annually.

Abington Neurological Associates (ANA), located at 1151 Old York Road, was a participating clinical trial site that contributed to the research and was involved in administering the first Leqembi infusions in Pennsylvania after its approval, according to a 2023 press release. 

ANA said they have treated over 100 patients with the medication to date. 

For all the latest news, follow us on Facebook or sign up for Glenside Local’s “Daily Buzz” newsletter here.